300 related articles for article (PubMed ID: 21517654)
1. Prevalence and economic burden of venous thromboembolism after total hip arthroplasty or total knee arthroplasty.
Baser O
Am J Manag Care; 2011 Feb; 17(1 Suppl):S6-8. PubMed ID: 21517654
[TBL] [Abstract][Full Text] [Related]
2. Economic impact of venous thromboembolism after hip and knee arthroplasty: potential impact of rivaroxaban.
Friedman RJ; Sengupta N; Lees M
Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):299-306. PubMed ID: 21671699
[TBL] [Abstract][Full Text] [Related]
3. Clinical and cost outcomes of venous thromboembolism in Medicare patients undergoing total hip replacement or total knee replacement surgery.
Baser O; Supina D; Sengupta N; Wang L; Kwong L
Curr Med Res Opin; 2011 Feb; 27(2):423-9. PubMed ID: 21192759
[TBL] [Abstract][Full Text] [Related]
4. Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population.
Vekeman F; LaMori JC; Laliberté F; Nutescu E; Duh MS; Bookhart BK; Schein J; Dea K; Olson WH; Lefebvre P
J Med Econ; 2011; 14(3):324-34. PubMed ID: 21506632
[TBL] [Abstract][Full Text] [Related]
5. Venous thromboembolism after total hip arthroplasty and total knee arthroplasty: current and future perspectives. Epilogue.
Merli G
Am J Manag Care; 2011 Feb; 17(1 Suppl):S33. PubMed ID: 21548181
[No Abstract] [Full Text] [Related]
6. Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty.
Kwong LM
Am J Manag Care; 2011 Feb; 17(1 Suppl):S22-6. PubMed ID: 21517652
[TBL] [Abstract][Full Text] [Related]
7. Quality improvement program: advancement of hospital venous thromboembolism--free zones.
Merli G
Am J Manag Care; 2011 Feb; 17(1 Suppl):S9-14. PubMed ID: 21517655
[TBL] [Abstract][Full Text] [Related]
8. In-hospital risk of venous thromboembolism and bleeding and associated costs for patients undergoing total hip or knee arthroplasty.
Vekeman F; LaMori JC; Laliberté F; Nutescu E; Duh MS; Bookhart BK; Schein J; Dea K; Olson WH; Lefebvre P
J Med Econ; 2012; 15(4):644-53. PubMed ID: 22356512
[TBL] [Abstract][Full Text] [Related]
9. An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement.
Lereun C; Wells P; Diamantopoulos A; Rasul F; Lees M; Sengupta N
J Med Econ; 2011; 14(2):238-44. PubMed ID: 21385145
[TBL] [Abstract][Full Text] [Related]
10. Improving outcomes in patients at risk for venous thromboembolism following total knee and total hip replacement: implications for managed care.
Navarro RP; Barr JE; Faubus K; Sabharwal AD; Stern E; Unger K
Am J Manag Care; 2011 Jul; 17 Suppl 9():S251-8. PubMed ID: 21819165
[TBL] [Abstract][Full Text] [Related]
11. Venous thromboembolism prophylaxis after total knee or hip replacement: treatment pattern and outcomes.
Penning-van Beest FJ; Overbeek JA; Meijer WM; Woodruff K; Jackson J; van der Vis H; van der Linden P; Herings RM
Pharmacoepidemiol Drug Saf; 2011 Sep; 20(9):972-8. PubMed ID: 21748826
[TBL] [Abstract][Full Text] [Related]
12. Prevention of venous thromboembolism after hip or knee arthroplasty: findings from a 2008 survey of US orthopedic surgeons.
Anderson FA; Huang W; Friedman RJ; Kwong LM; Lieberman JR; Pellegrini VD;
J Arthroplasty; 2012 May; 27(5):659-66.e5. PubMed ID: 22035977
[TBL] [Abstract][Full Text] [Related]
13. Venous thromboembolism after total hip arthroplasty and total knee arthroplasty: current and future perspectives.
Merli G
Am J Manag Care; 2011 Feb; 17(1 Suppl):S4-5. PubMed ID: 21548183
[No Abstract] [Full Text] [Related]
14. The ACCP guidelines for thromboprophylaxis in total hip and knee arthroplasty.
Colwell CW
Orthopedics; 2009 Dec; 32(12 Suppl):67-73. PubMed ID: 20201479
[TBL] [Abstract][Full Text] [Related]
15. Venous thromboembolic disease after total hip and knee arthroplasty: current perspectives in a regulated environment.
Pellegrini VD; Sharrock NE; Paiement GD; Morris R; Warwick DJ
Instr Course Lect; 2008; 57():637-61. PubMed ID: 18399613
[TBL] [Abstract][Full Text] [Related]
16. Stress-induced hyperglycaemia and venous thromboembolism following total hip or total knee arthroplasty: analysis from the RECORD trials.
Cohn DM; Hermanides J; DeVries JH; Kamphuisen PW; Kuhls S; Homering M; Hoekstra JB; Lensing AW; Büller HR
Thromb Haemost; 2012 Feb; 107(2):225-31. PubMed ID: 22187097
[TBL] [Abstract][Full Text] [Related]
17. Population-based epidemiology of postoperative venous thromboembolism in Taiwanese patients receiving hip or knee arthroplasty without pharmacological thromboprophylaxis.
Wu PK; Chen CF; Chung LH; Liu CL; Chen WM
Thromb Res; 2014 May; 133(5):719-24. PubMed ID: 24593913
[TBL] [Abstract][Full Text] [Related]
18. Thromboprophylaxis following hip and knee arthroplasty.
Mirkazemi C; Bereznicki LR; Peterson GM
Intern Med J; 2013 Feb; 43(2):124-9. PubMed ID: 23402484
[TBL] [Abstract][Full Text] [Related]
19. Analysis of venous thromboprophylaxis duration and outcomes in orthopedic patients.
Wells PS; Borah BJ; Sengupta N; Supina D; McDonald HP; Kwong LM
Am J Manag Care; 2010 Nov; 16(11):857-63. PubMed ID: 21348557
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of novel anticoagulants and potential economic implications.
Nutescu E
Am J Manag Care; 2011 Feb; 17(1 Suppl):S27-32. PubMed ID: 21517653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
